These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 6088126)

  • 1. Evidence for decreased endogenous dopamine and opioid inhibitory influences on LH secretion in polycystic ovary syndrome.
    Cumming DC; Reid RL; Quigley ME; Rebar RW; Yen SS
    Clin Endocrinol (Oxf); 1984 Jun; 20(6):643-8. PubMed ID: 6088126
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impairment of dopaminergic and opioidergic activity in patients with polycystic ovarian disease is restored by treatment for the induction of ovulation.
    Nappi C; Petraglia F; Di Carlo C; De Rosa R; Zaccardo A; Genazzani AR; Montemagno U
    Gynecol Obstet Invest; 1989; 27(1):38-41. PubMed ID: 2920972
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of ovarian surgery on the dopaminergic and opioidergic control of gonadotropin and prolactin secretion in women with polycystic ovarian disease.
    Szilágyi A; Hole R; Keckstein J; Rossmanith WG
    Gynecol Endocrinol; 1993 Sep; 7(3):159-66. PubMed ID: 8291452
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The role of the endogenous opioid system in the pathogenesis of polycystic ovary syndrome: the altered neuroendocrine regulation of GnRH-LH is corrected after clomiphene therapy].
    Barletta C; Vagiri D; Scavo D
    Minerva Endocrinol; 1992; 17(3):107-19. PubMed ID: 1298870
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Opioidergic regulation of LH pulsatility in women with polycystic ovary syndrome.
    Berga SL; Yen SS
    Clin Endocrinol (Oxf); 1989 Feb; 30(2):177-84. PubMed ID: 2532984
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Central opioid activity in polycystic ovary syndrome with and without dopaminergic modulation.
    Barnes RB; Lobo RA
    J Clin Endocrinol Metab; 1985 Oct; 61(4):779-82. PubMed ID: 3928677
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Parallelism in the luteinizing hormone responses to opioid and dopamine antagonists in hyperprolactinemic women with pituitary microadenoma.
    Seki K; Kato K; Shima K
    J Clin Endocrinol Metab; 1986 Nov; 63(5):1225-8. PubMed ID: 3760121
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evidence for increased dopaminergic and opioid activity in patients with hypothalamic hypogonadotropic amenorrhea.
    Quigley ME; Sheehan KL; Casper RF; Yen SS
    J Clin Endocrinol Metab; 1980 May; 50(5):949-54. PubMed ID: 6246138
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of endogenous opiates in the mechanism of inhibited luteinizing hormone (LH) secretion in women with anorexia nervosa: the effect of naloxone on LH, follicle-stimulating hormone, prolactin, and beta-endorphin secretion.
    Baranowska B; Rozbicka G; Jeske W; Abdel-Fattah MH
    J Clin Endocrinol Metab; 1984 Sep; 59(3):412-6. PubMed ID: 6086696
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of dopamine and metoclopramide in polycystic ovary syndrome.
    Barnes RB; Mileikowsky GN; Cha KY; Spencer CA; Lobo RA
    J Clin Endocrinol Metab; 1986 Aug; 63(2):506-9. PubMed ID: 3722335
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypothalamic opioid mechanisms in experimental uremic hypogonadism.
    Dong QH; Handelsman DJ
    Endocrinology; 1990 Mar; 126(3):1498-503. PubMed ID: 2137774
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metoclopramide effect on serum prolactin LH and FSH in patients with polycystic ovary syndrome.
    Prelević GM; Würzburger MI; Perić LA
    J Endocrinol Invest; 1988 Apr; 11(4):255-9. PubMed ID: 3137253
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Opioid effects on plasma concentrations of luteinizing hormone and prolactin in the adult male rhesus monkey.
    Gilbeau PM; Almirez RG; Holaday JW; Smith CG
    J Clin Endocrinol Metab; 1985 Feb; 60(2):299-305. PubMed ID: 2981242
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endogenous opioid peptides and the control of the menstrual cycle.
    Ferin M; Vande Wiele R
    Eur J Obstet Gynecol Reprod Biol; 1984 Dec; 18(5-6):365-73. PubMed ID: 6098492
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interaction between hypothalamic dopaminergic and opioidergic systems in the photoperiodic regulation of pulsatile luteinizing hormone secretion in sheep.
    Tortonese DJ
    Endocrinology; 1999 Feb; 140(2):750-7. PubMed ID: 9927302
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuroendocrinology of opioid peptides and their role in the control of gonadotropin and prolactin secretion.
    Yen SS; Quigley ME; Reid RL; Ropert JF; Cetel NS
    Am J Obstet Gynecol; 1985 Jun; 152(4):485-93. PubMed ID: 2990210
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of antagonists of dopamine and opiates on the basal and GnRH-induced secretion of luteinizing hormone, follicle stimulating hormone and prolactin during lactational amenorrhoea in breastfeeding women.
    Tay CC; Glasier AF; McNeilly AS
    Hum Reprod; 1993 Apr; 8(4):532-9. PubMed ID: 8501180
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The disappearance of opioidergic regulation of gonadotropin secretion in postmenopausal women.
    Reid RL; Quigley ME; Yen SS
    J Clin Endocrinol Metab; 1983 Dec; 57(6):1107-10. PubMed ID: 6313728
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The dopaminergic inhibition of LH secretion during the menstrual cycle.
    Ropert JF; Quigley ME; Yen SS
    Life Sci; 1984 May; 34(21):2067-73. PubMed ID: 6427547
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serotonin but not dopamine is involved in the naloxone-induced luteinizing hormone release in man.
    Foresta C; Scanelli G; Tramarin A; Scandellari C
    Fertil Steril; 1985 Mar; 43(3):447-50. PubMed ID: 3979585
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.